Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Sponsor: Intra-Cellular Therapies, Inc.
Terminated
Business Decision; No Safety or Efficacy Concerns
Other terminated trials from Intra-Cellular Therapies, Inc.
- Schizophrenia · Phase PHASE2 · Sep 2020
- Agitation in Dementia, Including Alzheimer's Disease · Phase PHASE3 · Jan 2019
More terminations from Intra-Cellular Therapies, Inc.
A PHASE1 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Intra-Cellular Therapies, Inc. and has accumulated 6 data snapshots since 2013. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intra-Cellular Therapies, Inc.
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .